Proteros and Eisai Achieve Target in Lead Discovery Project
News May 07, 2013
Proteros biostructures GmbH announced the successful completion of an integrated lead discovery collaboration with Eisai Co., Ltd. Based on Proteros’ structure guided discovery platform, various series of Lead Compounds were developed within a period of 10 months.
The developed compound series showed single digit nanomolar Kd values, as well as optimized binding kinetics and kinetic selectivity. Hits were identified out of the Proteros fragment library and the optimization process was driven by high quality protein crystallography as well as kinetic and thermodynamic profiling and the seamless interactions between Eisai and Proteros medicinal and computational chemists.
Dr. Lars Neumann, Vice President Discovery Projects and Project Manager stated: “We are very satisfied with the course of the project and are pleased to deliver the lead compound series to our partner Eisai Co., Ltd. We look forward to contributing further to the success of the Eisai research pipeline using our unique technology platform.”
Nanoparticles show great promise as diagnostic tools and drug delivery agents. But until now, most nanoparticles had to be injected into the bloodstream because they weren’t absorbed well orally. Now, researchers have modified nanoparticles to improve their uptake in the gastrointestinal tract.